Session 12B: The importance of diverse community engagement in clinical trials and how can we adopt a more inclusive approach to increase access to all participants
Tracks
Track 2
| Friday, October 24, 2025 |
| 11:25 AM - 12:10 PM |
Overview
Sponsored by: PARATUS CLINICAL
Details
It is important that clinical trial participants represent the real-world population that has (or are at risk of) the disease being studied. Ensuring the trial data represents real-world outcomes.
When clinical trials include diverse participants, the study results can have a much wider applicability. Representative trials allow for better prediction of outcomes across ethnicity, sex, socio-demographics, environment amongst other factors.
Some populations have higher occurrence of certain diseases:
Indigenous Australians have higher rates of chronic diseases (such as diabetes and cardiovascular disease)
People in rural areas have higher rates of arthritis, COPD and mental health disorders
Lower socio-demographic areas often have higher rates of chronic diseases
The panel will explore best practice in helping to educate and inform diverse populations about clinical trials, debunking myths and overcoming historical reluctance due to negative experience and/or perceptions, so everyone is able to make unbiased decisions that are correctly informed.
Sponsored by:
Speaker
Carly Agnew
Local Innovation Leader, Clinical Studies Unit Australia & New Zealand
Sanofi
Chair
Dr. Jhodie Duncan
General Manager Research and Partnerships
Latrobe Regional Health
Panellist
Megan Morrison
Chief Executive Officer
Paratus Clinical
Panellist
Jaspreet Sidhu
Implementation Lead, National Clinical Trials Governance Framework
The Alfred Hospital
Panellist
